Systematic Financial Management LP reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,409 shares of the company’s stock after selling 1,260 shares during the period. Systematic Financial Management LP’s holdings in Eli Lilly and were worth $1,680,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in LLY. BlackRock Inc. lifted its holdings in shares of Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares during the period. Winslow Capital Management LLC lifted its holdings in shares of Eli Lilly and by 79.7% during the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after acquiring an additional 1,719,538 shares during the period. Harbour Capital Advisors LLC increased its position in Eli Lilly and by 7,919.1% during the 2nd quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock worth $20,721,000 after purchasing an additional 1,684,072 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Eli Lilly and by 93.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after purchasing an additional 1,441,200 shares in the last quarter. Institutional investors and hedge funds own 75.66% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 770,000 shares of company stock worth $64,669,850. Company insiders own 0.20% of the company’s stock.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.88 EPS.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.
A number of analysts recently issued reports on the stock. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Leerink Swann increased their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $89.76.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.